Profil bibliographique

Emilie Rederstorff

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

23Publications signalées

389Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Colorectal Cancer Treatments and StudiesOsteoarthritis Treatment and MechanismsCancer Immunotherapy and BiomarkersCancer Treatment and PharmacologyGenetic factors in colorectal cancer

Publications récentes

Accès ouvert 2025 articleOpenAlex

Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial

Marion Thibaudin, Nicolas Roussot, Chloé Burlot, Antonin Schmitt et autres

5 citationsSignal Transduction and Targeted Therapy

Accès ouvert 2024 articleOpenAlex

Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer

Jean-David Fumet, Nicolas Roussot, Aurélie Bertaut, Emeric Limagne et autres

1 citationFuture Oncology

Accès ouvert 2024 articleOpenAlex

43P Single-arm phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients

François Ghiringhelli, Nicolas Roussot, Aurélie Bertaut, Hélène Bellio et autres

0 citationsAnnals of Oncology

2024 articleOpenAlex

54P Phase I dose-escalation study of trifluridine/tipiracil plus XB2001 and bevacizumab in chemorefractory advanced colorectal cancer: The TASKIN study

Nicolas Roussot, Marion Thibaudin, Chloé Burlot, Antonin Schmitt et autres

0 citationsAnnals of Oncology

Accès ouvert 2023 articleOpenAlex

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer

Nicolas Roussot, Jean-David Fumet, Emeric Limagne, Marion Thibaudin et autres

10 citationsBMC Cancer

2023 conference-abstractOpenAlex

Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.

Jean-David Fumet, Aurélie Bertaut, Nicolas Roussot, Hélène Bellio et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2023 articleOpenAlex

Performance of a blood-based RNA signature for gemcitabine-based treatment in metastatic pancreatic adenocarcinoma

David Piquemal, Roman Bruno, Barbara Bournet, François Ghiringhelli et autres

5 citationsJournal of Gastrointestinal Oncology

Accès ouvert 2023 erratumOpenAlex

Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”

Jean-David Fumet, Nicolás Isambert, Alice Hervieu, Sylvie Zanetta et autres

1 citationESMO Open

Accès ouvert 2022 articleOpenAlex

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study

Sylvain Ladoire, Emilie Rederstorff, Vincent Goussot, Sophie Parnalland et autres

4 citationsEuropean Journal of Cancer

2022 articleOpenAlex

Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach

Manon Réda, Pauline Macaire, Hélène Bellio, Lionel Uwer et autres

1 citationCancer Chemotherapy and Pharmacology

2021 articleOpenAlex

1707P A single G-CSF administration is enough to limit neutropenia in patients treated by eribulin

Antonin Schmitt, Manon Réda, Pauline Macaire, Hélène Bellio et autres

1 citationAnnals of Oncology

2021 articleOpenAlex

147P When a single G-CSF administration is better than longer duration: Example in patients treated by eribulin

Antonin Schmitt, Manon Réda, Pauline Macaire, Hélène Bellio et autres

0 citationsAnnals of Oncology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.